HeartBeam, Inc.

https://www.heartbeam.com/

HeartBeam, Inc. is a medical technology company based in Santa Clara, California, focused on developing advanced ambulatory Electrocardiogram (ECG) solutions. The company's mission is to transform cardiac care by providing clinical-grade ECG insights outside traditional clinical settings, empowering both patients and physicians with actionable cardiac data at the onset of arrhythmia symptoms.

The company's core technology is a proprietary and patented Vector Electrocardiography (VECG) platform, which includes a credit card-sized, cable-free 3D ECG device. This device captures the heart's electrical signals in three dimensions and synthesizes them into a 12-lead ECG for arrhythmia assessment. HeartBeam offers an app-based solution for rhythm monitoring, cloud-based diagnostic software, and has partnered with HeartNexus for a 24/7 cardiologist reader service. The company targets market segments such as remote patient monitoring and hospital emergency rooms, with an initial commercialization strategy focused on high-value preventive cardiology practices.

HeartBeam has achieved significant regulatory milestones, including FDA 510(k) clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. Led by CEO Robert Eno, the company is entering its initial commercialization phase and recently closed a $10 million public offering in April 2026 to support these efforts and further development. HeartBeam is also engaged in a strategic collaboration with the Icahn School of Medicine at Mount Sinai to advance AI-driven cardiac monitoring and develop predictive algorithms.

Latest updates

HeartBeam Schedules Q1 2026 Earnings Call, Highlights Commercial Launch Progress

Event summary

  • HeartBeam (BEAT) will host a Q1 2026 earnings conference call on May 13, 2026, at 4:30 PM Eastern Time.
  • CEO Robert Eno and CFO Timothy Cruickshank will lead the call, followed by a Q&A session.
  • The company will provide updates on its limited commercial launch for arrhythmia assessment and developments in extended-wear patch, heart attack detection, and AI initiatives.
  • HeartBeam received FDA clearance for arrhythmia assessment in December 2024 and for 12-Lead ECG synthesis software in December 2025.

The big picture

HeartBeam is attempting to disrupt cardiac care with its cable-free ECG technology, but faces the challenges inherent in bringing novel medical devices to market. The company’s limited commercial launch represents a critical inflection point, as it transitions from regulatory approvals to generating meaningful revenue. The success of this launch will determine whether HeartBeam can establish a sustainable competitive advantage in the crowded medical device space.

What we're watching

Commercial Traction
The success of HeartBeam’s limited commercial launch for arrhythmia assessment will be a key indicator of market adoption and revenue potential, given the company’s reliance on this initial rollout.
AI Integration
The company’s progress on AI initiatives will be critical for long-term differentiation and expansion into new applications beyond arrhythmia assessment, and the results will reveal the strategic direction of the company's technology.
Regulatory Landscape
Further FDA approvals for the extended-wear patch and heart attack detection capabilities will be essential for HeartBeam to expand its product offerings and market reach, and the timing of these approvals will significantly impact future growth.

HeartBeam Secures $10 Million in Public Offering, Led by Customer

Event summary

  • HeartBeam (BEAT) closed a public offering of 12.5 million shares, raising $10 million in gross proceeds.
  • The offering was led by HeartBeam’s first commercial customer, ClearCardio, and included participation from executive leadership, board members, existing investors, and institutional investors.
  • Titan Partners, a division of American Capital Partners, served as the sole bookrunner.
  • Proceeds will be allocated to commercialization, product development (extended-wear patch, heart attack detection), AI enhancement, and general corporate purposes.
  • The offering was made under a shelf registration statement filed with the SEC on March 13, 2026, which became effective on March 17, 2026.

The big picture

HeartBeam’s capital raise underscores the ongoing demand for remote cardiac monitoring solutions, driven by an aging population and a shift towards preventative healthcare. The involvement of ClearCardio, a first commercial customer, is a notable validation of HeartBeam’s technology, but also introduces a potential concentration risk. The $10 million raise provides a runway for continued development and commercialization, but the company will need to demonstrate a clear path to sustainable revenue generation.

What we're watching

Customer Alignment
ClearCardio’s participation in the offering signals a degree of confidence in HeartBeam’s technology and potential for integration, but also introduces a dependency that warrants monitoring.
Burn Rate
The allocation of proceeds to multiple initiatives (commercialization, development, AI) suggests a potentially high burn rate, and the company’s ability to achieve profitability will depend on efficient execution and rapid adoption.
Regulatory Risk
While HeartBeam has secured FDA clearances, continued innovation and expansion of its product offerings will remain subject to ongoing regulatory scrutiny and potential delays.

HeartBeam Raises $10 Million as Commercial Customer Joins Offering

Event summary

  • HeartBeam priced a public offering of 12.5 million shares at $0.80 per share, raising gross proceeds of $10 million.
  • The offering includes a 30-day option for underwriters to purchase an additional 1.875 million shares.
  • ClearCardio, HeartBeam’s first commercial customer, participated in the offering.
  • Proceeds will be used to support commercialization, product development (extended-wear patch, heart attack detection), AI enhancement, and working capital.
  • The offering is expected to close on or about April 16, 2026.

The big picture

HeartBeam's capital raise underscores the ongoing need for funding in the medical technology sector, particularly for companies focused on innovative cardiac monitoring solutions. The participation of ClearCardio, a first customer, is a notable endorsement, but also highlights the company's reliance on early adoption for validation. The offering's pricing suggests investor caution regarding the company's path to profitability.

What we're watching

Customer Validation
ClearCardio’s participation signals early validation of HeartBeam’s technology and market positioning, but the long-term impact on adoption and revenue remains to be seen.
Capital Efficiency
The $10 million raise, while helpful, requires HeartBeam to demonstrate capital efficiency in executing its commercialization and development plans to avoid needing further financing rounds.
AI Integration
The stated intention to enhance AI capabilities suggests a strategic pivot; the success of this initiative will hinge on demonstrating tangible improvements in diagnostic accuracy and workflow efficiency.

HeartBeam to Raise Capital Amidst Commercialization Push

Event summary

  • HeartBeam (BEAT) announced a proposed public offering of common stock, details of which are subject to market conditions.
  • The offering will be led by Titan Partners, a division of American Capital Partners.
  • Proceeds will be used to commercialize the FDA-cleared 12-lead synthesized ECG system, advance extended-wear patch and heart attack detection initiatives, and enhance AI capabilities.
  • The shelf registration statement (File No. 333-293307) was declared effective by the SEC on March 17, 2026.

The big picture

HeartBeam's public offering reflects the increasing investor interest in digital health solutions and remote patient monitoring. The company's focus on cable-free ECG technology positions it within a competitive landscape of cardiac diagnostic companies, but the FDA clearances provide a degree of validation. The size and terms of the offering will be a key indicator of investor confidence in HeartBeam's commercialization strategy and its ability to scale its technology.

What we're watching

Capital Allocation
The success of HeartBeam's initiatives hinges on efficient allocation of the raised capital, particularly given the ambitious goals outlined for commercialization and AI development.
Market Adoption
The pace of adoption of HeartBeam’s cable-free ECG technology will determine the return on investment and the company’s ability to achieve profitability.
Regulatory Risk
Future FDA clearances and regulatory pathways for the extended-wear patch and heart attack detection initiatives will significantly impact HeartBeam’s growth trajectory.

HeartBeam Advances Commercialization, Burns Cash in Pursuit of ECG Platform

Event summary

  • HeartBeam received FDA 510(k) clearance in December 2025 for its 12-lead ECG synthesis software.
  • The company initiated a limited market release, partnering with ClearCardio, a preventive cardiology practice serving thousands of patients.
  • HeartBeam enrolled the first patients in the ALIGN-ACS pilot study for heart attack detection, targeting enrollment completion shortly.
  • Cash and cash equivalents totaled $4.4 million as of December 31, 2025, with net cash used in operating activities of $2.9 million for the three-month period ended December 31, 2025.
  • HeartBeam appointed Bryan Humbarger as Chief Commercial Officer to lead commercial strategy.

The big picture

HeartBeam is attempting to disrupt the cardiac monitoring market with its cable-free, 3D ECG technology, positioning itself as a platform for both arrhythmia and heart attack detection. The company's reliance on partnerships like ClearCardio and collaborations with Mount Sinai highlights a strategy of leveraging external expertise to accelerate development and commercialization. However, the significant net losses and cash burn raise concerns about the company's long-term financial sustainability and ability to achieve profitability.

What we're watching

Commercial Traction
The success of the limited market release with ClearCardio will be a key indicator of broader adoption potential, given the staged rollout approach.
Cash Runway
HeartBeam's cash burn rate, currently at $4.4 million, requires careful monitoring as the company scales commercialization efforts and continues R&D.
Regulatory Expansion
The ALIGN-ACS pilot study's results will be critical in determining the feasibility of future FDA indication expansion for heart attack assessment, unlocking a large potential market.

HeartBeam Partners with Mount Sinai to Advance AI-Powered Cardiac Monitoring

Event summary

  • HeartBeam and Mount Sinai have initiated a strategic collaboration focused on developing and validating AI-ECG algorithms.
  • The partnership leverages HeartBeam’s 3D ECG platform and Mount Sinai’s clinical data resources and AI expertise.
  • A core focus is generating longitudinal, high-fidelity synthesized 12-lead ECG datasets for AI training, previously inaccessible.
  • The collaboration aims to expand HeartBeam’s clinical and commercial opportunities, potentially unlocking new reimbursement pathways.

The big picture

The partnership reflects a growing trend towards decentralized cardiac monitoring and the increasing reliance on AI to improve diagnostic accuracy and personalize treatment. HeartBeam’s ability to generate longitudinal ECG data from home settings addresses a critical gap in AI training data, potentially disrupting traditional clinical workflows and expanding the market for remote cardiac care. The collaboration positions HeartBeam to capitalize on the expanding remote patient monitoring market, estimated to reach billions in the coming years.

What we're watching

Regulatory Approval
The success of this collaboration hinges on securing regulatory approvals for the AI-ECG algorithms developed, which could significantly impact HeartBeam's market entry and revenue generation.
Data Integration
The ability to effectively integrate HeartBeam’s real-world ECG data with Mount Sinai’s clinical annotations will be crucial for training robust and accurate AI models, and any friction here could delay progress.
Commercial Adoption
Widespread adoption of HeartBeam’s platform will depend on demonstrating clinical utility and cost-effectiveness to physicians and payers, a challenge that requires more than just technological innovation.

HeartBeam to Showcase Extended Wear Patch, Targets Investor Meetings

Event summary

  • HeartBeam executives will present at the Oppenheimer Healthcare MedTech & Services Conference (March 16-17) and the ROTH Conference (March 23-24).
  • The company will demo its FDA-cleared HeartBeam System and a prototype 12-lead ECG extended wear patch at ACC.26 (March 28-30).
  • CEO Robert Eno, CFO Timothy Cruickshank, Founder and President Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will participate in the events.
  • The 12-lead ECG extended wear patch is currently a prototype and not FDA-approved.

The big picture

HeartBeam’s aggressive conference schedule signals a push to accelerate commercialization following FDA clearances for its arrhythmia assessment and 12-lead ECG synthesis software. The unveiling of the extended wear patch prototype suggests an ambition to expand its product offering and potentially compete in the remote patient monitoring market, a segment attracting significant investment. However, the prototype status highlights the ongoing regulatory and development hurdles the company faces.

What we're watching

Commercialization
The success of the investor meetings and ACC.26 demos will be a key indicator of HeartBeam’s ability to secure partnerships and drive adoption of its existing and future products.
Regulatory Risk
The lack of FDA approval for the extended wear patch introduces regulatory risk, and the company’s strategy for securing approval will be critical to its long-term success.
Execution Risk
HeartBeam’s ability to effectively demonstrate the value proposition of its technology to physicians and potential industry partners at ACC.26 will influence its ability to secure future contracts and partnerships.

HeartBeam Enrolls First Patients in Heart Attack Detection Pilot

Event summary

  • HeartBeam initiated the ALIGN-ACS pilot study on March 5, 2026, enrolling the first patients at the University Clinical Center of Serbia.
  • The study aims to enroll 100 patients presenting with chest pain in emergency rooms, comparing HeartBeam’s device with standard 12-lead ECGs.
  • HeartBeam received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025.
  • The pilot study builds on prior proof-of-concept studies suggesting HeartBeam’s 3D ECG technology can detect heart attacks with similar accuracy to standard ECGs.

The big picture

HeartBeam’s pilot study addresses a significant unmet need in cardiology: rapid, accessible heart attack detection outside of clinical settings. The company’s technology aims to reduce the ‘symptom-to-door’ time, a key driver of mortality and healthcare costs. While the market for remote cardiac monitoring is growing, HeartBeam faces the challenge of demonstrating clinical utility and securing widespread adoption among physicians and hospitals.

What we're watching

Clinical Validation
The success of the ALIGN-ACS pilot study is critical; failure to demonstrate efficacy relative to standard ECGs could significantly delay future FDA approval and commercialization.
Adoption Rate
The speed at which emergency room physicians and hospitals integrate HeartBeam’s technology into their workflows will dictate the pace of revenue generation and market penetration.
Competitive Landscape
The emergence of competing remote cardiac monitoring solutions or alternative diagnostic technologies could erode HeartBeam’s potential market share and pricing power.

HeartBeam Secures First Customer, ClearCardio, in Preventive Cardiology Push

Event summary

  • HeartBeam has landed ClearCardio as its first commercial customer, marking a key milestone for the company.
  • ClearCardio plans to invest in HeartBeam, signaling strategic alignment between the two organizations.
  • The agreement is structured as a Letter of Intent (LOI) pending a definitive agreement and staged rollout.
  • HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software in December 2025.
  • ClearCardio specializes in preventive cardiology and utilizes AI-powered imaging and diagnostics.

The big picture

HeartBeam's partnership with ClearCardio validates its strategy of targeting high-value, proactive healthcare segments. The agreement suggests a shift towards more accessible and convenient cardiac monitoring solutions, driven by patient demand for proactive health management and physician interest in differentiated tools. This move positions HeartBeam to capitalize on the growing preventive cardiology market, which is increasingly focused on early detection and personalized intervention.

What we're watching

Execution Risk
The success of this partnership hinges on a seamless rollout and integration of HeartBeam’s technology into ClearCardio’s existing patient programs, which could be complicated by differing workflows and physician adoption rates.
Business Model
The viability of HeartBeam’s subscription-based model will be tested as the company expands to additional concierge care networks and executive health programs, and the initial pricing structure may need adjustment based on patient uptake and feedback.
Competitive Landscape
The emergence of cable-free ECG technology could attract new entrants and intensify competition within the preventive cardiology market, potentially impacting HeartBeam’s market share and pricing power.

HeartBeam Appoints Commercial Chief to Drive Limited Launch

Event summary

  • HeartBeam appointed Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026.
  • The role is newly created and focuses on commercial strategy and execution for the company’s limited launch.
  • Humbarger previously served as Chief Commercial Officer at Proprio, a venture-backed surgical guidance company.
  • HeartBeam received FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software in December 2025.

The big picture

HeartBeam's appointment of a seasoned commercial leader signals a shift towards aggressive market penetration following FDA clearances. The company's focus on partnerships and reference sites suggests a recognition of the challenges in introducing disruptive medical technology and a need to validate real-world performance. This move is indicative of a broader trend in MedTech towards patient-centric, remote monitoring solutions, but HeartBeam will need to demonstrate a clear clinical and economic advantage to displace incumbents.

What we're watching

Execution Risk
The success of HeartBeam’s limited launch hinges on Humbarger’s ability to rapidly establish reference sites and partnerships within the cardiology community, which could be hampered by physician adoption rates.
Channel Dynamics
How effectively Humbarger can build and manage channel partners will determine the scalability of HeartBeam’s commercial efforts beyond the initial limited launch.
Competitive Landscape
The competitive pressure from established players like AliveCor and Heartflow will likely intensify as HeartBeam attempts to gain market share with its novel 3D ECG technology.

HeartBeam Management to Meet Investors at JP Morgan Healthcare Conference

Event summary

  • HeartBeam executives Robert Eno (CEO) and Timothy Cruickshank (CFO) will attend the JP Morgan 2026 Healthcare Conference, January 12-15.
  • The company will host off-site meetings with investors and potential commercialization partners.
  • The conference follows FDA 510(k) clearance for HeartBeam’s 12-lead ECG synthesis software, granted in December 2025.
  • HeartBeam plans a limited U.S. commercial launch in Q1 2026 targeting concierge and preventive cardiology practices.

The big picture

HeartBeam's technology addresses the growing demand for remote patient monitoring and at-home diagnostics, a market fueled by rising healthcare costs and patient preference for convenience. The FDA clearance and upcoming commercial launch represent a critical inflection point for the company, but its long-term success hinges on demonstrating clinical utility and achieving broader adoption beyond the initial target practices. The company’s reliance on a synthesized ECG, rather than a full diagnostic, introduces a unique regulatory and clinical validation challenge.

What we're watching

Commercialization
The success of the Q1 2026 limited launch will be a key indicator of HeartBeam’s ability to penetrate the market and validate its go-to-market strategy, particularly given the reliance on concierge and preventative cardiology practices.
Wearable Integration
The company’s plans for wearable integration could significantly expand its addressable market, but depend on successful partnerships and seamless data integration, which carries execution risk.
Regulatory Scope
The limitations outlined in the FDA clearance regarding arrhythmia assessment will constrain HeartBeam’s initial applications and require careful messaging to avoid regulatory scrutiny as the platform expands.
CID: 291